• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Bromobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Bromobenzenes

Recent Advances in the Study of 1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine (CAS: 843608-46-8)

1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine (CAS: 843608-46-8) is a fluorinated amine derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of novel pharmaceuticals targeting central nervous system (CNS) disorders and metabolic diseases. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug discovery.

One of the most notable advancements in the study of 1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine is its application in the synthesis of trifluoromethyl-containing compounds, which are increasingly recognized for their enhanced metabolic stability and bioavailability. A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient use of this compound as a building block for the development of selective serotonin reuptake inhibitors (SSRIs) with improved pharmacokinetic profiles. The researchers highlighted the compound's ability to introduce trifluoromethyl groups into complex molecular frameworks, thereby enhancing the drug-like properties of the resulting molecules.

In addition to its synthetic utility, 1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine has been investigated for its direct biological effects. A recent preclinical study published in Bioorganic & Medicinal Chemistry Letters reported that this compound exhibits moderate inhibitory activity against certain enzymes involved in neurodegenerative pathways. Specifically, it showed promise as a potential lead compound for the treatment of Alzheimer's disease, with in vitro assays indicating its ability to modulate amyloid-beta aggregation. However, further in vivo studies are required to validate these findings and assess its therapeutic potential.

The compound's mechanism of action and structure-activity relationships (SAR) have also been a focus of recent research. Computational modeling and molecular docking studies have provided insights into how the bromophenyl and trifluoroethylamine moieties contribute to its binding affinity with target proteins. These studies, published in ACS Chemical Neuroscience, suggest that the compound's unique electronic properties, conferred by the fluorine atoms, play a critical role in its interactions with biological targets. Such insights are invaluable for the rational design of next-generation therapeutics.

Despite these promising developments, challenges remain in the large-scale synthesis and optimization of 1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine. A 2024 review in Organic Process Research & Development highlighted the need for more efficient and sustainable synthetic routes to produce this compound at an industrial scale. Recent efforts have focused on catalytic methods and green chemistry approaches to address these challenges, with some success in improving yield and reducing environmental impact.

In conclusion, 1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine (CAS: 843608-46-8) represents a versatile and promising compound in the realm of chemical biology and drug discovery. Its applications range from serving as a key synthetic intermediate to exhibiting direct biological activity, particularly in the context of CNS disorders. Ongoing research aims to further elucidate its therapeutic potential and optimize its synthesis for broader use in the pharmaceutical industry. Future studies should focus on advancing preclinical evaluations and exploring its utility in other therapeutic areas.

• 843608-54-8((1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine)
• 878539-31-2((S)-1-(3-Bromophenyl)-2,2,2-trifluoroethanamine)
• 842169-72-6(1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine hydrochloride)
• 336105-43-2((s)-1-(4-Bromophenyl)-2,2,2-trifluoroethanamine Hydrochloride)
• 843608-53-7((1R)-1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine)
• 778565-93-8((1S)-1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine)
• 842169-71-5(1-(3-Bromo-phenyl)-2,2,2-trifluoro-ethylamine hydrochloride)
• 842169-83-9((R)-1-(4-Bromophenyl)-2,2,2-trifluoroethanamine hydrochloride)
• 878408-46-9((s)-1-(3-Bromophenyl)-2,2,2-trifluoroethan-1-amine Hydrochloride Salt)
• 843608-45-7(1-(3-bromophenyl)-2,2,2-trifluoroethan-1-amine)